Mitsubishi Electric Corp. Takeshi Sugiyama apologized for causing trouble and will resign to take responsibility for test data falsifications on equipment supplied to railway firms that may date back over 30 years.
Sugiyama, who held a news conference to make the announcements, added that the company will investigate the deception by a committee headed by an outside lawyer and would reveal the results and measures to prevent a recurrence in September.
Mitsubishi Electric officials admitted faking testing data on air conditioning units and pneumatic devices used in braking systems and doors that were supplied to the train companies.
Both products are manufactured at the company's plant in Togitsu, Nagasaki Prefecture.
The company did not follow specifications by railway companies on several test items, including capability.
It also created fake data and included it in test reports. The practice may have begun around 1985.
The company also created a computer program to crank out fake test data on the equipment that is supplied to give the appearance that tests were done.


U.S. Dollar Slides Toward Biggest Annual Loss Since 2017 as 2026 Risks Loom
South Korea Factory Activity Returns to Growth in December on Export Rebound
South Korea Factory Output Misses Forecasts in November Amid Ongoing Economic Uncertainty
Oil Prices Slip Slightly as Markets Weigh Geopolitical Risks and Supply Glut Concerns
Newmont Goldcorp Expects Lower Q1 2026 Gold Output After Western Australia Bushfire
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry
Tesla UK Sales Slide as Competition Intensifies, While BYD Surges in Electric Vehicle Market
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
Citi Forecasts a Volatile but Ongoing Bull Market for S&P 500 in 2026
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Forex Markets Hold Steady as Traders Await Fed Minutes Amid Thin Year-End Volumes
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year
Japanese Business Leaders Urge Government Action as Weak Yen Strains Economy
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 



